Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04879407 · ClinicalTrials.gov registry record
Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data
A clinical trial of Pulmonary Embolism, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 98,947
- Enrollment target
- 1
- Study location
NCT04879407: Completed study of Pulmonary Embolism, sponsored by Brigham and Women's Hospital.
NCT04879407 is a study of Pulmonary Embolism that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 98,947 participants, above the 997-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (9824% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04879407, a study of Pulmonary Embolism, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 98,947 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Claims-based algorithm: see attached protocol for full definition
Conditions Studied
Interventions
- DRUG Warfarin
- DRUG Rivaroxaban
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98,947 participants |
| Start Date | 2020-10-10 |
| Est. Completion | 2021-06-11 |
What the finished NCT04879407 record still lists
NCT04879407 is an observational study that tracks outcomes without assigning an intervention. Its 98,947 participants enrollment target places it among the larger protocols in the corpus, above the 997-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (9824% higher).
The record links to 1 condition, with Pulmonary Embolism appearing as the primary indexed condition, and to 2 interventions - of which Warfarin is the first listed.
NCT04879407 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04879407 about?
NCT04879407 is a clinical study titled "Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT04879407?
This trial is currently completed. The enrollment target is 98,947 participants. The study started on 2020-10-10. Estimated completion is 2021-06-11.
What conditions does trial NCT04879407 study?
This clinical trial studies the following conditions: Pulmonary Embolism.
What interventions are being tested in trial NCT04879407?
The interventions under investigation include: Warfarin (DRUG), Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT04879407?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04879407 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Embolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04879407's enrollment target sits among peer trials
98,947 1st of 48 higher than 48 of 48 other Pulmonary Embolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Embolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Mobility Outcomes in Post-Pulmonary Embolic Disease
RECRUITING · NA
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
RECRUITING · NA
-
The PERSEVERE Study
RECRUITING · NA
-
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
RECRUITING
-
Supplemental Oxygen in Pulmonary Embolism (SO-PE)
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01351545 · 99,999 participants
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- NCT03277365 · 100,000 participants · NA
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
- NCT04281823 · 100,000 participants
DeBakey Cardiovascular Magnetic Resonance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI